Back to top
more

Arcellx (ACLX)

(Delayed Data from NSDQ)

$65.92 USD

65.92
701,526

+2.57 (4.06%)

Updated Jul 16, 2024 04:00 PM ET

After-Market: $65.89 -0.03 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arcellx (ACLX) delivered earnings and revenue surprises of 72.55% and 32.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 763.64% and 10.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

How Arcellx (ACLX) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Arcellx (ACLX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Arcellx, Inc. (ACLX) delivered earnings and revenue surprises of 166.67% and 163.52%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Gilead (GILD), Compugen Collaborate for Immunotherapy Program

by Zacks Equity Research

Gilead (GILD) enters into a license agreement with Compugen for its pre-clinical immunotherapy program.

The Zacks Analyst Blog Highlights Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics

by Zacks Equity Research

Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics are included in this Analyst Blog.

Biotech Stock Roundup: BMY's Drug Approval, VRTX & CRSP Gene Therapy Get MHRA Nod

by Zacks Equity Research

Bristol Myers (BMY) and Vertex (VRTX) drug approvals are in focus in the biotech sector.

Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead

by Zacks Equity Research

Arcellx (ACLX) and Gilead (GILD) expand their existing collaboration in cancer treatment. This deal is expected to close by year-end.

Is a Surprise Coming for Arcellx (ACLX) This Earnings Season?

by Zacks Equity Research

Arcellx (ACLX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Ekta Bagri headshot

4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates

by Ekta Bagri

Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.

Roblox (RBLX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Roblox's (RBLX) third-quarter 2023 performance is expected to have benefited from growth in engagement hours and daily active users.

Take-Two (TTWO) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Take-Two's (TTWO) fiscal second-quarter performance is expected to have been dented by rising operating expenses despite portfolio strength.

What Awaits Warner Bros. Discovery (WBD) in Q3 Earnings?

by Zacks Equity Research

Warner Bros. Discovery's (WBD) third-quarter results are likely to reflect slow advertising revenues and subscriber growth in viewership amid cost-cutting measures.

Disney (DIS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Disney's (DIS) fiscal fourth-quarter results are expected to reflect declining Disney+ subscriber growth rate amid stiff competition.

Are Medical Stocks Lagging Arcellx (ACLX) This Year?

by Zacks Equity Research

Here is how Arcellx, Inc. (ACLX) and Ardelyx (ARDX) have performed compared to their sector so far this year.

Is Arcellx (ACLX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Arcellx, Inc. (ACLX) and BellRing Brands (BRBR) have performed compared to their sector so far this year.

Wall Street Analysts Believe Arcellx, Inc. (ACLX) Could Rally 35.56%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 35.6% in Arcellx, Inc. (ACLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Ekta Bagri headshot

5 Biotech Stocks to Buy as New Drug Approvals Drive Industry Prospects

by Ekta Bagri

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position EXEL, DVAX, ACLX, ANIP and VNDA well amid volatility.

Gilead's (GILD) Leukemia Study Progress Put on Clinical Hold

by Zacks Equity Research

Gilead (GILD) faces a setback as the FDA puts a partial clinical hold on enrolling new patients in studies evaluating magrolimab for treating AML in the United States.

Does Arcellx, Inc. (ACLX) Have the Potential to Rally 39.12% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 39.1% in Arcellx, Inc. (ACLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Gilead (GILD), Tentarix To Develop Cancer, Inflammation Therapies

by Zacks Equity Research

Gilead (GILD) enters into a deal with Tentarix Biotherapeutics to discover and develop novel therapies for cancer and inflammation.

Gilead (GILD) Ends Myelodysplastic Syndromes Study on Magrolimab

by Zacks Equity Research

Gilead Sciences, Inc. (GILD) discontinues phase III ENHANCE study, evaluating the potential of magrolimab as a treatment for higher-risk myelodysplastic syndromes, due to futility based on a planned analysis.

Biotech Stock Roundup: DICE Gains on LLY Buyout, MRSN Down on Update & More

by Zacks Equity Research

Acquisition and regulatory updates from DICE and GSK plc (GSK ) are in focus in the biotech sector.

Arcellx (RCLX) Down on Hold for Lead Program CART-ddBCMA

by Zacks Equity Research

Arcellx's (ACLX) study on lead program CART-ddBCMA for treating adult patients with relapsed or refractory multiple myeloma has been put on hold by the FDA. The company's shares decline on the same.

Arcellx, Inc. (ACLX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Arcellx, Inc. (ACLX) delivered earnings and revenue surprises of -123.02% and 86.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?